IPD Stock Overview A medical technology company, manufactures, and sells bioimpedance spectroscopy (BIS) technology medical devices in the Unites States and Europe. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
ImpediMed Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for ImpediMed Historical stock prices Current Share Price AU$0.053 52 Week High AU$0.16 52 Week Low AU$0.042 Beta 2.89 1 Month Change -3.64% 3 Month Change -7.02% 1 Year Change -62.14% 3 Year Change -69.71% 5 Year Change -67.88% Change since IPO -93.76%
Recent News & Updates
Non-Executive Director recently bought AU$76k worth of stock Nov 29
ImpediMed Limited to Report Q1, 2025 Results on Oct 22, 2024 Oct 15
ImpediMed Limited, Annual General Meeting, Nov 19, 2024 Sep 27
Price target decreased by 8.8% to AU$0.15 Sep 09
Consensus revenue estimates decrease by 14% Sep 04
Board Member recently bought AU$73k worth of stock Sep 03 See more updates
Non-Executive Director recently bought AU$76k worth of stock Nov 29
ImpediMed Limited to Report Q1, 2025 Results on Oct 22, 2024 Oct 15
ImpediMed Limited, Annual General Meeting, Nov 19, 2024 Sep 27
Price target decreased by 8.8% to AU$0.15 Sep 09
Consensus revenue estimates decrease by 14% Sep 04
Board Member recently bought AU$73k worth of stock Sep 03
Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 30
Forecast to breakeven in 2027 Aug 29
ImpediMed Limited to Report Fiscal Year 2024 Results on Aug 29, 2024 Aug 23
Forecast to breakeven in 2026 Jul 30 ImpediMed Limited Appoints Parmjot Bains as CEO on an ongoing basis
We Think ImpediMed (ASX:IPD) Can Afford To Drive Business Growth Jun 26
ImpediMed Limited Appoints Fiona Bones as A Non-Executive Director Jun 08
New minor risk - Market cap size Jun 04
Independent Non-Executive Director recently bought AU$50k worth of stock May 15
ImpediMed Limited to Report Q3, 2024 Results on Apr 30, 2024 Apr 20
Price target decreased by 9.6% to AU$0.18 Apr 16
ImpediMed to Present Chronic Breast Cancer-Related Lymphedema Study Results at American Society of Breast Surgeons Annual Meeting Apr 11
Independent Non-Executive Director recently bought AU$100k worth of stock Mar 28
ImpediMed (ASX:IPD) Is In A Good Position To Deliver On Growth Plans Mar 05
Consensus revenue estimates decrease by 13% Mar 04
Independent Non-Executive Director recently bought AU$90k worth of stock Mar 02
Price target decreased by 12% to AU$0.19 Feb 03
No longer forecast to breakeven Feb 03
High number of new and inexperienced directors Feb 01
New minor risk - Share price stability Jan 31
ImpediMed Limited to Report First Half, 2024 Results on Feb 27, 2024 Jan 23
Independent Non-Executive Director recently bought AU$135k worth of stock Dec 19
Companies Like ImpediMed (ASX:IPD) Are In A Position To Invest In Growth Nov 23
Consensus revenue estimates decrease by 20% Nov 21 ImpediMed Limited Announces CFO Changes
Price target decreased by 16% to AU$0.23 Nov 10
Price target increased by 21% to AU$0.27 Nov 01
ImpediMed Limited to Report Q1, 2024 Results on Oct 31, 2023 Oct 24
ImpediMed Limited, Annual General Meeting, Nov 30, 2023 Oct 12
High number of new directors Oct 05
ImpediMed Limited Announce the Appointment of Steven Chen as Chief Medical Officer Sep 27
Consensus revenue estimates decrease by 23% Sep 06
Full year 2023 earnings: EPS and revenues miss analyst expectations Aug 31
Full year 2023 earnings: EPS and revenues miss analyst expectations Aug 31
ImpediMed Limited, Annual General Meeting, Sep 28, 2023 Aug 18
Price target increased by 27% to AU$0.21 Jul 21
ImpediMed Limited to Report Q4, 2023 Results on Jul 24, 2023 Jul 17
Is ImpediMed (ASX:IPD) In A Good Position To Deliver On Growth Plans? Jul 11
ImpediMed Limited Appoints Daniel Sharp as Director Jul 06
Executive Director recently bought AU$144k worth of stock Jun 28
Independent Non-Executive Chairman recently bought AU$82k worth of stock Jun 14
No longer forecast to breakeven May 30
MD, CEO & Director recently bought AU$52k worth of stock Apr 22
MD, CEO & Director recently bought AU$54k worth of stock Mar 31
Price target increased by 25% to AU$0.18 Mar 29
We Think ImpediMed (ASX:IPD) Needs To Drive Business Growth Carefully Mar 27
MD, CEO & Director recently bought AU$64k worth of stock Mar 08
First half 2023 earnings released: AU$0.01 loss per share (vs AU$0.006 loss in 1H 2022) Feb 25
Price target decreased by 7.7% to AU$0.17 Jan 31
ImpediMed Limited to Report Q2, 2023 Results on Jan 30, 2023 Jan 24
ImpediMed Limited Presents New Data at 2022 San Antonio Breast Cancer Symposium Shows Early Detection Using L-Dex and Intervention Improves Lymphedema Progression-Free Survival Dec 16 Impedimed Limited Announces CEO Changes
ImpediMed Limited Announces Management Changes Nov 22
Less than half of directors are independent Nov 16
Executive Director & Interim CEO recently bought AU$164k worth of stock Nov 01
Less than half of directors are independent Oct 28
ImpediMed Limited Announces Current Data Support Early Detection and Intervention to Reduce Rates of Breast Cancer Related Lymphedema Oct 27
ImpediMed Limited to Report Q1, 2023 Results on Oct 19, 2022 Oct 13
ImpediMed Expands Use of SOZO in Leading Cancer Centers Focused on Reducing the Impact of Lymphedema after Breast Cancer Oct 12
ImpediMed Announces U.S. Launch of Lymphedema Prevention Program with GenesisCare a Global Organization Dedicated to Care of Cancer Patients Oct 05
Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation Sep 28
Consensus forecasts updated Sep 04
Price target decreased to AU$0.18 Aug 31
ImpediMed Limited Announces Board Changes Aug 30
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 30
ImpediMed Limited, Annual General Meeting, Oct 26, 2022 Aug 29
Price target decreased to AU$0.22 Aug 03
ImpediMed Limited Announces Executive Changes Jul 27
Less than half of directors are independent Jul 27 ImpediMed Limited Announces Resignation of Richard Carreon as Managing Director
We're Not Worried About ImpediMed's (ASX:IPD) Cash Burn Jun 10
ImpediMed Limited Announces Release of the New Version 4.1 Software for the SOZO Digital Health Platform Jun 02
No longer forecast to breakeven Apr 27
ImpediMed Limited to Report Q3, 2022 Results on Apr 28, 2022 Apr 22
New Bone Data Showing Strong Correlation Between ImpediMed's SOZO and DXA in Cancer Patients Presented At 39Th Annual Miami Breast Cancer Conference Mar 07
No longer forecast to breakeven Mar 04
Consensus revenue estimates fall by 21% Mar 03
First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Feb 28
Now 24% undervalued Feb 22
Now 21% undervalued Feb 03
A Look At The Fair Value Of ImpediMed Limited (ASX:IPD) Feb 01
Price target increased to AU$0.32 Nov 04
Forecast to breakeven in 2024 Nov 02
Price target increased to AU$0.25 Oct 20 Shareholder Returns IPD AU Medical Equipment AU Market 7D -1.9% -1.1% -2.7% 1Y -62.1% 0.4% 6.5%
See full shareholder returns
Return vs Market: IPD underperformed the Australian Market which returned 6.5% over the past year.
Price Volatility Is IPD's price volatile compared to industry and market? IPD volatility IPD Average Weekly Movement 7.5% Medical Equipment Industry Average Movement 8.8% Market Average Movement 8.0% 10% most volatile stocks in AU Market 16.8% 10% least volatile stocks in AU Market 3.1%
Stable Share Price: IPD has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: IPD's weekly volatility (8%) has been stable over the past year.
About the Company ImpediMed Limited, a medical technology company, manufactures, and sells bioimpedance spectroscopy (BIS) technology medical devices in the Unites States and Europe. The company offers SOZO, a noninvasive BIS device for the clinical assessment of lymphedema and deliver snapshot of fluid status and tissue composition; L-Dex analysis for lymphedema; BodyComp Analysis, a point-of-car body composition analysis; and HF-Dex analysis for point-or care heart failure fluid assessment. It also provides SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications.
Show more ImpediMed Limited Fundamentals Summary How do ImpediMed's earnings and revenue compare to its market cap? IPD fundamental statistics Market cap AU$103.20m Earnings (TTM ) -AU$19.79m Revenue (TTM ) AU$10.32m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) IPD income statement (TTM ) Revenue AU$10.32m Cost of Revenue AU$1.31m Gross Profit AU$9.01m Other Expenses AU$28.80m Earnings -AU$19.79m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -0.0098 Gross Margin 87.27% Net Profit Margin -191.78% Debt/Equity Ratio 0%
How did IPD perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 14:36 End of Day Share Price 2024/12/23 00:00 Earnings 2024/06/30 Annual Earnings 2024/06/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources ImpediMed Limited is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Dennis Hulme APP Securities Pty Ltd. Russell Wright Barclay Pearce Capital Pty Limited Matthijs Smith Canaccord Genuity
Show 7 more analysts 
